mTOR in Human Diseases
The mechanistic target of rapamycin (mTOR) is a major signaling intermediary that coordinates favorable environmental conditions with cell growth. Indeed, as part of two functionally distinct protein complexes, named mTORC1 and mTORC2, mTOR regulates a variety of cellular processes, including protei...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book Chapter |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2019
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 05085naaaa2201393uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_54029 | ||
| 005 | 20210211 | ||
| 020 | |a books978-3-03921-061-9 | ||
| 020 | |a 9783039210619 | ||
| 020 | |a 9783039210602 | ||
| 024 | 7 | |a 10.3390/books978-3-03921-061-9 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 100 | 1 | |a Dormond, Olivier |4 auth | |
| 245 | 1 | 0 | |a mTOR in Human Diseases |
| 260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2019 | ||
| 300 | |a 1 electronic resource (480 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a The mechanistic target of rapamycin (mTOR) is a major signaling intermediary that coordinates favorable environmental conditions with cell growth. Indeed, as part of two functionally distinct protein complexes, named mTORC1 and mTORC2, mTOR regulates a variety of cellular processes, including protein, lipid, and nucleotide synthesis, as well as autophagy. Over the last two decades, major molecular advances have been made in mTOR signaling and have revealed the complexity of the events implicated in mTOR function and regulation. In parallel, the role of mTOR in diverse pathological conditions has also been identified, including in cancer, hamartoma, neurological, and metabolic diseases. Through a series of articles, this book focuses on the role played by mTOR in cellular processes, metabolism in particular, and highlights a panel of human diseases for which mTOR inhibition provides or might provide benefits. It also addresses future studies needed to further characterize the role of mTOR in selected disorders, which will help design novel therapeutic approaches. It is therefore intended for everyone who has an interest in mTOR biology and its application in human pathologies. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by-nc-nd/4.0/ |2 cc |4 https://creativecommons.org/licenses/by-nc-nd/4.0/ | ||
| 546 | |a English | ||
| 653 | |a n/a | ||
| 653 | |a primary cilia | ||
| 653 | |a neurodegeneration | ||
| 653 | |a nutrient sensor | ||
| 653 | |a PI3K | ||
| 653 | |a transcriptomics | ||
| 653 | |a phosphorylation | ||
| 653 | |a metabolic reprogramming | ||
| 653 | |a autophagy | ||
| 653 | |a Alzheimer's disease | ||
| 653 | |a rapalogs | ||
| 653 | |a liver | ||
| 653 | |a angiogenesis | ||
| 653 | |a mTOR complex | ||
| 653 | |a MBSCs | ||
| 653 | |a advanced biliary tract cancers | ||
| 653 | |a Medulloblastoma | ||
| 653 | |a epithelial to mesenchymal transition | ||
| 653 | |a AMPK | ||
| 653 | |a p70S6K | ||
| 653 | |a lipid metabolism | ||
| 653 | |a thyroid cancer | ||
| 653 | |a sodium iodide symporter (NIS)/SLC5A5 | ||
| 653 | |a male fertility | ||
| 653 | |a anesthesia | ||
| 653 | |a illumina | ||
| 653 | |a mTOR inhibitor | ||
| 653 | |a miRNA | ||
| 653 | |a Hutchinson-Gilford progeria syndrome (HGPS) | ||
| 653 | |a eIFs | ||
| 653 | |a Emery-Dreifuss muscular dystrophy (EDMD) | ||
| 653 | |a glucose | ||
| 653 | |a AKT | ||
| 653 | |a oral cavity squamous cell carcinoma (OSCC) | ||
| 653 | |a glucose and lipid metabolism | ||
| 653 | |a cellular signaling | ||
| 653 | |a aging | ||
| 653 | |a tumor microenvironment | ||
| 653 | |a rapamycin | ||
| 653 | |a leukemia | ||
| 653 | |a chloral hydrate | ||
| 653 | |a rapalogues | ||
| 653 | |a schizophrenia | ||
| 653 | |a T-cell acute lymphoblastic leukemia | ||
| 653 | |a senescence | ||
| 653 | |a lamin A/C | ||
| 653 | |a neurotoxicity | ||
| 653 | |a neurodevelopment | ||
| 653 | |a inhibitor | ||
| 653 | |a methamphetamine | ||
| 653 | |a pulmonary fibrosis | ||
| 653 | |a mTOR | ||
| 653 | |a mTOR inhibitors | ||
| 653 | |a combination therapy | ||
| 653 | |a proteolysis | ||
| 653 | |a fluid shear stress | ||
| 653 | |a tumour cachexia | ||
| 653 | |a biomarkers | ||
| 653 | |a synapse | ||
| 653 | |a gluconeogenesis | ||
| 653 | |a mTOR signal pathway | ||
| 653 | |a Sertoli cells | ||
| 653 | |a immunosenescence | ||
| 653 | |a miRNome | ||
| 653 | |a protein aggregation | ||
| 653 | |a senolytics | ||
| 653 | |a metabolism | ||
| 653 | |a NGS | ||
| 653 | |a mTORC2 | ||
| 653 | |a mTORC1 | ||
| 653 | |a metabolic diseases | ||
| 653 | |a IonTorrent | ||
| 653 | |a apoptosis | ||
| 653 | |a dopamine receptor | ||
| 653 | |a nocodazole | ||
| 653 | |a microenvironment | ||
| 653 | |a everolimus | ||
| 653 | |a acute myeloid leukemia | ||
| 653 | |a immunotherapy | ||
| 653 | |a spermatogenesis | ||
| 653 | |a bone remodeling | ||
| 653 | |a signalling | ||
| 653 | |a targeted therapy | ||
| 653 | |a ageing | ||
| 653 | |a therapy | ||
| 653 | |a NVP-BEZ235 | ||
| 653 | |a fructose | ||
| 653 | |a physical activity | ||
| 653 | |a laminopathies | ||
| 653 | |a MC3T3-E1 cells | ||
| 653 | |a cell signaling | ||
| 653 | |a microRNA | ||
| 653 | |a cancer | ||
| 653 | |a lipolysis | ||
| 653 | |a melatonin | ||
| 653 | |a Parkinson's disease | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/1355 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/54029 |7 0 |z DOAB: description of the publication |